Albers FC, Licskai C, Chanez P, et al. - Given a range of doses and administration routes have been utilized in past investigations exploring the link between blood eosinophil count and mepolizumab treatment outcomes in severe eosinophilic asthma, researchers performed this post hoc meta-analysis to report data from patients taking the licensed dose of mepolizumab [100 mg subcutaneously (SC)] or placebo only. They used data from the MENSA (MEA115588/NCT01691521) and MUSCA (200862/NCT02281318) trials. Either mepolizumab 100 mg SC or 75 mg intravenously, or placebo plus standard of care every 4 weeks, was administered to patients (≥ 12 years) with severe eosinophilic asthma who suffered ≥ 2 exacerbations in the previous year. By 45%–85% decrease in annual clinically significant exacerbation rates, by 60%–70% reduction in exacerbations needing hospitalization/emergency room visit, and rise in the odds of no clinically significant exacerbations across all eosinophil threshold subgroups were provided by mepolizumab vs placebo. In subgroups ≥ 150 cells/μL, an improvement in all other secondary endpoints was seen in relation to treatment with mepolizumab. Findings revealed that patients with baseline blood eosinophil count ≥ 150 cells/μL experienced consistent clinical benefits of mepolizumab, this implies that this cut-off is proven as suitable for detecting patients responsive to the licensed mepolizumab dose.